Company Overview and News

 
UK home improvement chain Homebase sold to Hilco for nominal sum by Wesfarmers

2018-05-25 proactiveinvestors.com.au
UK home improvement chain Homebase is being sold for a nominal sum by Wesfarmers (ASX:WES) just two years after the Australian retail conglomerate bought the business.

 
Homebase drags down profits of Australian owner Wesfarmers in second half

2018-02-21 proactiveinvestors.com.au
UK DIY company Homebase contributed to a sharp fall in profits for its Australian owner Wesfarmers in the second half.

 
S&P/ASX 200 recovers losses to finish slightly up, A2M up 29%

2018-02-21 proactiveinvestors.com.au
Gains in the Consumer Staples sector, +3.38%, more than offset losses in the Materials sector, -2.25%.

 
S&P/ASX 200 breaks into positive territory in the afternoon, A2M up 26%

2018-02-21 proactiveinvestors.com.au
S&P/ASX 200 (INDEXASX:XJO) (ASX:XJO) has recovered early losses to be trading up for the day with an hour to go.

 
S&P/ASX 200 recovers morning losses to be flat around midday, A2M up 25%

2018-02-21 proactiveinvestors.com.au
S&P/ASX 200 (INDEXASX:XJO) (ASX:XJO) has recovered 25 points from its morning low to be flat just after midday.

 
S&P/ASX 200 opens lower as expected but begins to bounce, BHP down near 5%

2018-02-20 proactiveinvestors.com.au
The ASX 200 is down 8 points or 0.2% to 5,933 just after opening bell this morning.

 
S&P/ASX 200 set to open lower after Dow Jones goes down 1%

2018-02-20 proactiveinvestors.com.au
Furthermore, BHP Billiton Limited (ASX:BHP) is set to drag the Australian market down today after failing to impress investors with its result yesterday after-market.

 
ASX All Ords rockets higher, holds gains to the close

2016-09-05 proactiveinvestors.com.au
Proactive Investors is a global leader in financial news, media, research and events focusing on emerging growth companies across four continents.

 
ASX All Ords drifts lower waiting for the U.S. Fed

2016-08-26 proactiveinvestors.com.au
Proactive Investors is a global leader in financial news, media, research and events focusing on emerging growth companies across four continents.

 
ASX All Ords heads lower as crucial U.S. Fed meeting nears

2016-08-25 proactiveinvestors.com.au
Proactive Investors is a global leader in financial news, media, research and events focusing on emerging growth companies across four continents.

 
ASX All Ords tip toes higher

2016-08-24 proactiveinvestors.com.au
Proactive Investors is a global leader in financial news, media, research and events focusing on emerging growth companies across four continents.

 
ASX All Ords gets back in the hunt for 12-month high

2016-08-23 proactiveinvestors.com.au
Proactive Investors is a global leader in financial news, media, research and events focusing on emerging growth companies across four continents.

 
ASX All Ords runs out of puff but holds 5600 barrier

2016-08-22 proactiveinvestors.com.au
Proactive Investors is a global leader in financial news, media, research and events focusing on emerging growth companies across four continents.

 
ASX All Ords trades in narrow band to end session flat

2016-08-17 proactiveinvestors.com.au
Proactive Investors is a global leader in financial news, media, research and events focusing on emerging growth companies across four continents.

 
ASX All Ords drifts lower by session end

2016-08-16 proactiveinvestors.com.au
Proactive Investors is a global leader in financial news, media, research and events focusing on emerging growth companies across four continents.

Related Articles

HRTX : Heron Therapeutics Analysis and Research Report

2018-05-25 - Asif

Overview Heron is a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments that address some of the most important unmet patient needs. Heron Therapeutics is developing novel, patient-focused solutions that apply its innovative science and technologies to already approved pharmacological agents for patients suffering from cancer or pain. On August 9, 2016, its first commercial product, SUSTOL, was approved by the FDA. The company developed SUSTOL for the prevention of chemotherapy-induced nausea and vomiting (“CINV”). SUSTOL is indicated, in combination with other antiemetics, in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy (“MEC”) or anthracycline and cyclophosphamide (“AC”) combination chemotherapy regimens. The company commenced commercial sales of SUSTOL in the U.S. in October 2016. On November 9, 2017...

ACIA: Acacia Communications Analysis and Research Report

2018-05-25 - Asif

Overview The company's mission is to deliver high-speed coherent optical interconnect products that transform communications networks, relied upon by cloud infrastructure operators and content and communication service providers, through improvements in performance and capacity and reductions in associated costs. By converting optical interconnect technology to a silicon-based technology, a process the company refer to as the siliconization of optical interconnect, the company believe Acacia Communications is leading a disruption that is analogous to the computing industry’s integration of multiple functions into a microprocessor. The company's products include a family of low-power coherent digital signal processor application-specific integrated circuits, or DSP ASICs, and silicon photonic integrated circuits, or silicon PICs, which Acacia Communications has integrated into families of optical interconnect modules with transmission speeds ranging from 100 to 400 gigabits per ...

ANTH: Anthera Pharmaceuticals Analysis and Research Report

2018-05-21 - Asif

Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...